{"filing":{"accession_number":"0001213900-26-073983","cik":"0001711754","ticker":"INMB","company_name":"Inmune Bio, Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ea0296624-8k_inmune.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026073983/ea0296624-8k_inmune.htm"},"events":[{"id":15267,"run_id":13624,"accession_number":"0001213900-26-073983","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"INmune Bio entered into a warrant inducement agreement allowing holders to exercise 647,112 warrants at a reduced exercise price of $1.40 (down from $1.95) and receive 647,112 shares of common stock, with the Company expecting to receive $905,957 in aggregate consideration. While this involves warrant exercise rather than a direct unregistered equity issuance, the economic substance is a dilutive capital raise through the inducement of warrant conversion at favorable terms to holders, generating cash proceeds and increasing share count. The extension of remaining warrant maturity to December 31, 2027 further incentivizes future dilution.","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":12962,"accession_number":"0001213900-26-073983","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"INmune Bio entered into a warrant inducement agreement allowing holders to exercise 647,112 warrants at a reduced exercise price of $1.40 (down from $1.95) and receive 647,112 shares of common stock, with the Company expecting to receive $905,957 in aggregate consideration. While this involves warrant exercise rather than a direct unregistered equity issuance, the economic substance is a dilutive capital raise through the inducement of warrant conversion at favorable terms to holders, generating cash proceeds and increasing share count. The extension of remaining warrant maturity to December 31, 2027 further incentivizes future dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:35:54.911864+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12962,"accession_number":"0001213900-26-073983","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"INmune Bio entered into a warrant inducement agreement allowing holders to exercise 647,112 warrants at a reduced exercise price of $1.40 (down from $1.95) and receive 647,112 shares of common stock, with the Company expecting to receive $905,957 in aggregate consideration. While this involves warrant exercise rather than a direct unregistered equity issuance, the economic substance is a dilutive capital raise through the inducement of warrant conversion at favorable terms to holders, generating cash proceeds and increasing share count. The extension of remaining warrant maturity to December 31, 2027 further incentivizes future dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:35:54.911864+00:00","company_name":"Inmune Bio, Inc.","ticker":"INMB","filing_date":"2026-07-01"}]}